Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Genetic risk score to predict biochemical recurrence after radical prostatectomy in prostate cancer: prospective cohort study.

Oh JJ, Park S, Lee SE, Hong SK, Lee S, Kim TJ, Lee IJ, Ho JN, Yoon S, Byun SS.

Oncotarget. 2017 May 26;8(44):75979-75988. doi: 10.18632/oncotarget.18275. eCollection 2017 Sep 29.

2.
3.

Correlation between postoperative prostate-specific antigen and biochemical recurrence in positive surgical margin patients: Single surgeon series.

Seo WI, Kang PM, Yoon JH, Kim W, Chung JI.

Prostate Int. 2017 Jun;5(2):53-58. doi: 10.1016/j.prnil.2017.02.002. Epub 2017 Mar 3.

4.

Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy.

Robertson NL, Sala E, Benz M, Landa J, Scardino P, Scher HI, Hricak H, Vargas HA.

J Urol. 2017 Jul;198(1):65-70. doi: 10.1016/j.juro.2017.02.071. Epub 2017 Feb 16.

PMID:
28216327
5.

PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.

VanderWeele DJ, Turkbey B, Sowalsky AG.

Expert Rev Precis Med Drug Dev. 2016;1(6):505-515. doi: 10.1080/23808993.2016.1267562. Epub 2016 Dec 12.

6.

Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer.

Almeida FD, Yen CK, Scholz MC, Lam RY, Turner J, Bans LL, Lipson R.

Am J Nucl Med Mol Imaging. 2017 Jan 15;7(1):1-11. eCollection 2017.

7.

Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality.

Pellegrini KL, Sanda MG, Patil D, Long Q, Santiago-Jiménez M, Takhar M, Erho N, Yousefi K, Davicioni E, Klein EA, Jenkins RB, Karnes RJ, Moreno CS.

BJU Int. 2017 Jun;119(6):961-967. doi: 10.1111/bju.13779. Epub 2017 Feb 11.

PMID:
28107602
8.

Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.

Holl EK, Brown MC, Boczkowski D, McNamara MA, George DJ, Bigner DD, Gromeier M, Nair SK.

Oncotarget. 2016 Nov 29;7(48):79828-79841. doi: 10.18632/oncotarget.12975.

9.

LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a.

Liu HT, Fang L, Cheng YX, Sun Q.

Cancer Med. 2016 Dec;5(12):3512-3519. doi: 10.1002/cam4.900. Epub 2016 Oct 28.

10.

Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.

Bach-Gansmo T, Nanni C, Nieh PT, Zanoni L, Bogsrud TV, Sletten H, Korsan KA, Kieboom J, Tade FI, Odewole O, Chau A, Ward P, Goodman MM, Fanti S, Schuster DM, Willoch F.

J Urol. 2017 Mar;197(3 Pt 1):676-683. doi: 10.1016/j.juro.2016.09.117. Epub 2016 Oct 13.

11.

Prediction of prostate cancer recurrence using quantitative phase imaging: Validation on a general population.

Sridharan S, Macias V, Tangella K, Melamed J, Dube E, Kong MX, Kajdacsy-Balla A, Popescu G.

Sci Rep. 2016 Sep 23;6:33818. doi: 10.1038/srep33818.

12.

Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population.

Chen L, Lei Z, Ma X, Huang Q, Zhang X, Zhang Y, Hao P, Yang M, Zhao X, Chen J, Liu G, Zheng T.

Sci Rep. 2016 Sep 19;6:33604. doi: 10.1038/srep33604.

13.

Impact of prior abdominal surgery on the outcomes after robotic - assisted laparoscopic radical prostatectomy: single center experience.

Kishimoto N, Takao T, Yamamichi G, Okusa T, Taniguchi A, Tsutahara K, Tanigawa G, Yamaguchi S.

Int Braz J Urol. 2016 Sep-Oct;42(5):918-924. doi: 10.1590/S1677-5538.IBJU.2015.0607.

14.

Evaluating deviations in prostatectomy patients treated with IMRT.

Sá AC, Peres A, Pereira M, Coelho CM, Monsanto F, Macedo A, Lamas A.

Rep Pract Oncol Radiother. 2016 May-Jun;21(3):266-70. doi: 10.1016/j.rpor.2015.11.004. Epub 2015 Dec 29.

15.

Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial?

Taguchi S, Shiraishi K, Fukuhara H, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y.

Radiat Oncol. 2016 Jul 30;11:102. doi: 10.1186/s13014-016-0671-1.

16.

Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy.

Kim SJ, Kim JH, Chang HK, Kim KH.

J Exerc Rehabil. 2016 Jun 30;12(3):143-7. doi: 10.12965/jer.1632646.323. eCollection 2016 Jun. Review.

17.

Patients treated with radical prostatectomy with positive digital rectal examination findings in the intermediate-risk group are prone to PSA recurrence.

Furubayashi N, Negishi T, Ura S, Mutaguchi J, Taguchi K, Shimokawa M, Nakamura M.

Oncol Lett. 2016 Jun;11(6):3882-3888. Epub 2016 Apr 20.

18.

Prostate Cancer Detection Using Composite Impedance Metric.

Khan S, Mahara A, Hyams ES, Schned AR, Halter RJ.

IEEE Trans Med Imaging. 2016 Dec;35(12):2513-2523. Epub 2016 Jun 9.

19.

Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation.

Huang Y, Pan XW, Li L, Chen L, Liu X, Lu JL, Zhu XM, Huang H, Yang QW, Ye JQ, Gan SS, Wang LH, Hong Y, Xu DF, Cui XG.

Oncotarget. 2016 Apr 19;7(16):22016-30. doi: 10.18632/oncotarget.7882.

20.

Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy? A meta-analysis.

Meng Y, Li H, Xu P, Wang J.

Int J Clin Exp Med. 2015 Dec 15;8(12):22319-27. eCollection 2015.

Supplemental Content

Support Center